News

REMINDER – Outset Medical, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the OM Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--$OM #OM--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and…

1 year ago

Evotec Announces Change in Management Board

Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024Distribution of responsibilities across other Management Board functions…

1 year ago

Britannia Life Sciences Inc. Reports Fourth Quarter and Fiscal Year Financial Results for 2024

Toronto, Ontario--(Newsfile Corp. - September 2, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased…

1 year ago

Health Kiosk Market Surges to USD 3.29 Billion by 2030, Propelled by 12.17% CAGR – Verified Market Reports®

The global Health Kiosk Market is driven by a combination of technological advancements, increasing healthcare awareness, and the rising demand…

1 year ago

Referral Management Market is expected to generate a revenue of USD 13.48 Billion by 2031, Globally, at 15.8% CAGR: Verified Market Research®

The Referral Management Market is driven by the increasing demand for coordinated patient care, the rising adoption of digital healthcare…

1 year ago

Seegene and Springer Nature Launch ‘Nature Awards MDx Impact Grants’ to Innovate Syndromic PCR Diagnostic Assays

-  Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation.-  Global research teams invited to…

1 year ago

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group…

1 year ago

Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

CAMBRIDGE, MA / ACCESSWIRE / September 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Taiwan Food & Drug…

1 year ago

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of…

1 year ago

Hemogenyx Pharmaceuticals PLC Announces CDX Development Update

CDX Development Update LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the…

1 year ago